March 2012

Business in Vancouver, March 20, 2012
From a sheer market perspective, Allon Therapeutics’ decision to focus on a rare a neurological disorder called progressive supranuclear palsy (PSP) doesn’t add up. After all, only 20,000 North Americans have the disease, compared with 4.4 million Alzheimer’s victims….